Figure 5.

HNRNPAB is inversely correlated with lnc-CTSLP4 in GC tissues and rescues the suppressive effects of lnc-CTSLP4 on GC cells

(A) Representative immunohistochemical staining of HNRNPAB in GC tumor tissues and adjacent non-tumor tissues (magnification: 200× and 400×). (B) The expression levels of HNRNPAB in 157 pairs of GC patients based on HNRNPAB IHC score (GC cohort 2, ∗∗∗p < 0.001). (C) Validation of HNRNPAB expression in GEPIA. (D) The expression levels of HNRNPAB in GC patients with different pathological stages based on HNRNPAB IHC score (∗∗p < 0.01, ∗∗∗p < 0.001). (E and F) The correlation of HNRNPAB expression levels and overall survival in the GSE14210 dataset (n = 118) and GSE14210, GSE15459, GSE22377, GSE29272, and GSE51105 dataset (n = 592) was analyzed by Kaplan-Meier plotter. (G) Kaplan-Meier survival analysis for OS of 157 patients with GC (GC cohort 2) reveals a statistically significant difference between the low HNRNPAB expression group (n = 129) and the high HNRNPAB group (n = 28). (H and I) Univariate (H) and multivariate (I) analysis of for prognostic features of GC patients (n = 157) showed that the expression of HNRNPAB was an independent prognostic factor for survival. (J) HNRNPAB is downregulated in the high lnc-CTSLP4 expression group compared to the low lnc-CTSLP4 expression group (GC cohort 2, ∗∗∗p < 0.001). (K and L) Correlation analysis of HNRNPAB with E-cadherin (K) or N-cadherin (L) in GC. (M and N) Validation of the relationship between HNRNPAB and E-cadherin (M) or Snail (N) based on GEPIA. (O–R) The metastatic abilities of GC cells (MGC803 and HGC27) after overexpression or shRNA knockdown of HNRNPAB (Transwell assays, magnification: 200×). (S and T) The metastatic abilities of GC cells (MGC803 and AGS cells) transfected with lnc-CTSLP4, HNRNPAB-expressing vector, or Snail si-RNA (Transwell assays, magnification: 200×, ∗∗∗p < 0.001).